The Systematic Evaluation of Alogliptin’s (Nesina) Cost-Effectiveness in Treating Type 2 Diabetes

Topic: The Systematic Evaluation of Alogliptin’s (Nesina) Cost-Effectiveness in Treating Type 2 Diabetes Order Description INSTRUCTIONS: Assume that your group is a P&T committee of a health plan and you are a member on the committee. There is a new drug that would like to get onto your health plan’s formulary. Please conduct a systematic review including all the pharmacoeconomic literature on the drug and make a recommendation whether or not the drug should be included on your health plan’s formulary based on the results of the systematic review you conducted. No more than 10 pages double-spaced excluding figure 1 and table 1. 1. You will use the paper "The Systematic Evaluation of Alogliptin’s (Nesina) Cost-Effectiveness in Treating Type 2 Diabetes" -This will be attached as a word document. 1. You will create Results, Discussion, Conclusion and Table 1 based on the attached paper. -SEE "INSTRUCTIONS" document for the Complete Instructions and for the Manuscript and Table 1 template. I highlighted the most important things in red. 2. Please see "Sample Article" document on how to make Table1. This will be attached as a word document. Table 1. Summary of Studies Included in the Review (see Table 1 in sample article “Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review”) 3.Please Explain...what is the meaning of " sensitivity and the specificity " on the first line of the second paragraph under "Methods" section on the paper(attached).- I highlighted in red color. 4. I need the copy of the articles that you mentioned in the paragraph. - "free-full texts, articles that were submitted within the last (5) five years". -You will find it on the first paragraph under "Methods" section. I highlighted in red on the paper. FOCUS OF THE PAPER: Focus of the paper--this paper should only focus on cost effectiveness of the drug and only review pharmacoeconomic studies on the drug 2. Inclusion of clinical trials--this paper should review both clinical trials and observational studies. 3. Availability of articles--if some articles meet all the inclusion and exclusion criteria but not available free of charge, please get a copy of the articles. Please incorporate the comments and make suggested changes. In your final submission, there should include a title page, revised introduction, revised methods, results, discussions, conclusion, revised figure 1, table 1, and complete references. References: AMA Style The references and articles need to be available or free access.